Consider this trade only after the price triggers.
A look at three names to consider in the biotech and biopharma space.
The game plan is to spot the charts that have more room to run.
Data and industry conferences will likely be catalysts for shares in the space.
When this stock hit my breakout scan, I paid it a bit of extra attention.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Wall Street discounting talk of bombing Syria from president.
Sometimes you miss trades or investments if you don't take a step back.
Chart indicators suggest Anthem may be ready for run at $300.
Stock markets ran higher as investors turned towards domestic-focused companies.

Columnist Conversations

Stock picking contests can be entertaining and can provide some interesting ideas but if you seriously want to...
Your Reality Check. Check out Real Money's Helene Meisler's latest podcast here. Subscribe to Meisler's T...
XBTUSD (Bitcoin) On 4/25 Bitcoin top ticked @ 9755.52 and then FELL. Our first short term support @ 8990 was...
join me after the close for a free webinar as we talk volatility and markets. https://attendee.gotowebina...


News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.